

302 366 5207
09/24/93 10:55

001

DU PONT CENTRAL RESEARCH AND DEVELOPMENT
HASKELL LABORATORY FOR TOXICOLOGY
AND INDUSTRIAL MEDICINE

cc: A.M. Kaplan
S.A. MacKenzie
G.L. Kennedy
B.W. Karrh

23 September 1993

TO: R.W. Rickard
C.F. Reinhardt

FROM: J.C. Cook

RE: Potentially Reportable Toxicity Data [TSCA 8(e)]

SUMMARY:

As part of a Haskell Laboratory Research Planning Group project (MR 5686), ammonium perfluorooctanoate (CB) was included in a mechanistic bioassay investigating extrahepatic tumor induction by compounds which produce peroxisome proliferation. CB is purchased from the 3M Company and is used by DuPont Polymers. In this mechanistic bioassay, 300 ppm CB was fed to rats for two years. In addition to an ad libitum control, a second control group was pair-fed to the 300 ppm CB group to control for the effects of reduced body weight. Increased incidences of combined (single, multiple) hepatic adenomas, Leydig cell adenomas, and pancreatic acinar cell adenomas were seen in the 300 ppm CB group when compared to either the ad libitum or pair-fed control (Table 1). The tumor incidences (liver, testis, pancreas) were outside the historical control incidence range for Haskell Laboratory. In addition, age-adjustment statistics also supported the conclusion that the tumor incidence was elevated for the liver (both controls), pancreas (pair-fed control), and testis (pair-fed control). In a previous two-year feeding study conducted by the 3M Company, an increased incidence of Leydig cell adenomas was reported at 300 ppm CB (The 3M Company, River/3M Exp. 02B1CR0012-Two-Year Oral (Diet) Toxicity/Carcinogenicity Study of Fluorochemical FC-143 in Rats). The Leydig cell tumor incidence in the 3M Company study was 0% (0 ppm), 6% (30 ppm), and 14% (300 ppm). Therefore, the increased incidence of hepatocellular and pancreatic acinar cell tumors in the mechanistic bioassay study was judged to be potentially reportable under TSCA 8E.

SPONSOR: Haskell Research Planning Group

9/24/93

COMPOUND NAME: Ammonium perfluorooctanoate (CB)
CAS Registry Number 3825-26-1

ROGER,

HASKELL NUMBER: 18623

EID924418

SPECIES: Rats

DOSES ADMINISTERED: 300 ppm, dietary administration

ADDITIONAL COMMENTS: None.

OFFICIAL NOTICE
OF FINDINGS
TSCA 8

CALL ME IF YOU
HAVE ANY
QUESTIONS

[Handwritten signature]

Post-It™ brand fax transmittal memo 7071		# of pages = 2
TO R. Zipfel	FROM G. Kennedy	
	CC	

AIP002114

09/24/93

10:55

002

TABLE 1
SUMMARY OF HYPERPLASIA/NEOPLASIA LESION INCIDENCE
IN THE LIVER, PANCREAS, AND TESTIS

<u>LESION</u>	<u>AD LIBITUM</u> <u>CONTROL</u>	<u>PAIR-FED</u> <u>CONTROL</u>	<u>300 PPM CB</u>
LIVER:			
Adenoma	2/80 (2.5)	1/79 (1.3)	7/76 (9.2)#
Multiple Adenoma	0/80 (0)	0/79 (0)	3/76 (3.9)
Combined Adenomas	2/80 (2.5)	1/79 (1.3)	10/76 (13.1)**
Carcinoma	0/80 (0)	2/79 (2.5)	0/76 (0)
Adenoma/Carcinoma Combined	2/80 (2.5)	3/79 (3.8)	10/76 (13.1)**
PANCREAS:			
Acinar Cell Adenoma	0/80 (0)	1/79 (1.3)	4/76 (5.2)
Multiple Acinar Cell Adenoma	0/80 (0)	0/79 (0)	3/76 (3.9)
Combined Adenomas	0/80 (0)	1/79 (1.3)	7/76 (9.2)**
Acinar Cell Carcinoma	0/80 (0)	0/79 (0)	1/76 (1.3)
Adenoma/Carcinoma Combined	0/80 (0)	1/79 (1.3)	8/76 (10.5)**
Acinar Hyperplasia	14/80 (17.5)	8/79 (10.1)	30/76 (39.5)**
TESTIS:			
Leydig Cell Adenoma	0/79 (0)	2/78 (2.6)	8/76 (10.5)**
Leydig Cell Hyperplasia	11/79 (13.9)	26/78 (33.3)	35/76 (46.0)*

* p < 0.05 compared to ad libitum control (Fisher's Exact test).

p < 0.05 compared to pair-fed control (Fisher's Exact test).

EID924419

AJP002115